Hypertension 2/e > Nephrology

The revised and updated 2nd Edition provides a logical, practical framework for managing patients with hypertension. Today’s leading experts discuss all aspects of the field—from pathophysiology, pharmacological treatments, and lifestyle modifications to secondary hypertension and cardiovascular complications. * Assesses the risks of specific pharmacological treatments * offers expert analysis of recent clinical trials * and provides * Delivers strategies for managing patients with comorbid conditions such as diabetes, renal disease, and ischemic heart disease. * Explains the role of vascular biology in the pathogenesis of hypertension

Section 1: Background and History
1. History of Clinical Hypertension
2. The National High Blood
Pressure Education Program
3. Epidemiology of Hypertension
Section 2: Pathophysiology
4. Pathophysiology of Hypertension
5. Blood Pressure Genetics
6. Sympathetic Nervous System in Acute and Chronic Blood Pressure
Evaluation
7. Evironmental and Psychosocial Stress in Hypertension
Onset and Progression
8. Renin
9. The Genetics of Salt-Related
Hypertension
10. Angiotensin Converting Enzyme: Properties and Function
11. Angiotensin 1-7
12. The Angiotensin Receptors: AT1 and AT2
13. Aldosterone and Mineralocorticoids
14. What is the Role of Insulin Resistance and Compulsory Hyperinsulinemia in the
Pathogenesis and Clinical Course of Patients with Essential Hypertension?
15. Remodelling of Resistance Arteries in Hypertension
16. Arterial Stiffness in Hypertension
17. Endothelium in Hypertension: Nitric Oxide
18. Endothelium in Hypertension: Endothelin, Prostanoids and Other Mediators.
19. The Natriuretic Peptides
20. Vasodilator Peptides: CGRP, Substance P, and Adrenomedullin
21. Kallikrein – Kinin Systems
Section 3: TargetOrgan Damage/Cardiovascular Events
22. The Concept of Total Risk
23. New Interpretations of Blood
Pressure: The Importance ofPulse Pressure
24. Coronary Atherosclerotic Sequelae of Hypertension
25. Left Ventricular Hypertrophy, Congestive Heart Failure, and Coronary Flow Reserve Abnormalities in Hypertension
26. Chronic Renal Insufficiency: Slowing its Progression
Section 4: Diagnosis
27. Initial Evaluation and Follow-up Assessment
28. Prognostic and Diagnostic Value of Ambulatory Blood Pressure Monitoring
29. White Coat Hypertension
Section 5: General Consideration
30. Benefits of Treating Hypertension: The Clinical Trialists Collaborative Group
31. The Antihypertensive and Lipid-Lowering to
Prevent Heart Attack Trial
32. The LIFE Study
33. The VALUE Trial
34. Clinical Outcome Trials of Hypertension with Angiotensin Receptor
Blockers
35. Clinical Trials in Hypertension and Diabetes
36. ACE Inhibitor Trials: Effects in Hypertension
37. Critical Assessment of Hypertension Guidelines
38. Current Prescribing Practices
39. Calcium Channel Blockers: Controversies, Lessons and Outcomes
40. Nursing Clinics in the Management of Hypertension
41. Community Outreach
42. Medication Adherence for Antihypertensive Therapy
Section 6: Diet and Nutrition
43. Micronutrients
44. Dietary Approaches to Hypertension Management: The DASH Studies
45. Obesity and Hypertension: Effects on the Cardiovascular and Renal Systems
46. Alcohol and Hypertension
47. Obesity in Hypertension: The Role of Diet and Drugs
48. Exercise and Hypertension
Section 7:Pharmacological Treatment
49. Initial Choices in the Treatment of Hypertension
50. Pharmacokinetics of Antihypertensive Drugs
51.Fixed Combination Antihypertensive Therapy
52. Chronotherapeutics in the Treatment of Hypertension
Section 8: Comorbid Conditions and Special Populations in Hypertension
53. Diabetes Mellitis and the Cardiovascular/Metabolic Syndrome: Reducing Cardiovascular and Renal Events
54. Hypertension in Patients
on Renal Replacement Therapy
55. Ischemic Heart Disease in Hypertension
56. Hypertension in the Elderly
57. Management of Hypertension in Black Populations
58. Hypertension in Pregnancy
59. Hypertension in Children
60. Resistant Hypertension
61. Orthostatic Hypotension and Autonomic Dysfunction Syndromes
Section 9: Individual Drug Classes
62. Diuretics: Mechanisms of Action
63. Beta-Adrenergic Blockers
64. Alpha-Adrenoceptor Blockers
65. Angiotensin Converting Enzyme Inhibitors
66. Calcium Antagonists
67. Angiotensin II Receptor Antagonists
68. Direct Acting Smooth Muscle Vasodilators and Adrenergic Inhibitors
69. Endothelin Antagonists
70. Mineralocorticoid Receptor Antagonists
71. Vasopeptidase Inhibitors
72. Renin Inhibitors
Section 10: Secondary Hypertension
73. Obstructive Sleep Apnea and Hypertension
74. Renovascular Hypertension: Diagnosis and Treatment
75. Adrenal Cortex Hypertension
76. Pheochromocytoma: Detection and Management
77. Anesthesia and Hypertension
78. Management of Hypertensive Emergencies and Urgencies
79. Aggressive Blood Pressure Targets: Developing Effective Algorithms

등록된 상품문의

상품문의 쓰기 새 창 더보기

상품문의가 없습니다.